PMC:7696151 / 23031-24923
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 698 | 124-132 | Species | denotes | patients | Tax:9606 |
| 699 | 275-292 | Species | denotes | hepatitis C virus | Tax:11103 |
| 700 | 452-460 | Species | denotes | patients | Tax:9606 |
| 701 | 477-494 | Species | denotes | hepatitis C virus | Tax:11103 |
| 702 | 665-673 | Species | denotes | patients | Tax:9606 |
| 703 | 959-967 | Species | denotes | patients | Tax:9606 |
| 704 | 1378-1385 | Species | denotes | patient | Tax:9606 |
| 705 | 1653-1660 | Species | denotes | patient | Tax:9606 |
| 706 | 294-297 | Species | denotes | HCV | Tax:11103 |
| 707 | 1581-1584 | Species | denotes | HCV | Tax:11103 |
| 708 | 264-267 | Chemical | denotes | HCQ | MESH:D006886 |
| 709 | 532-535 | Chemical | denotes | HCQ | MESH:D006886 |
| 710 | 541-561 | Chemical | denotes | pegylated interferon | |
| 711 | 566-575 | Chemical | denotes | ribavirin | MESH:D012254 |
| 712 | 809-829 | Chemical | denotes | pegylated interferon | |
| 713 | 860-869 | Chemical | denotes | ribavirin | MESH:D012254 |
| 714 | 905-908 | Chemical | denotes | HCQ | MESH:D006886 |
| 715 | 971-976 | Chemical | denotes | HCQ + | MESH:D006886 |
| 716 | 1113-1118 | Chemical | denotes | HCQ + | MESH:D006886 |
| 717 | 1252-1257 | Chemical | denotes | HCQ + | MESH:D006886 |
| 718 | 1473-1476 | Chemical | denotes | HCQ | MESH:D006886 |
| 719 | 1788-1796 | Chemical | denotes | steroids | MESH:D013256 |
| 720 | 1813-1816 | Chemical | denotes | HCQ | MESH:D006886 |
| 721 | 1820-1832 | Chemical | denotes | sulfadiazine | MESH:D013411 |
| 722 | 0-15 | Disease | denotes | Hepatitis virus | MESH:D006525 |
| 723 | 90-103 | Disease | denotes | liver disease | MESH:D008107 |
| 724 | 191-200 | Disease | denotes | cirrhosis | MESH:D005355 |
| 725 | 224-236 | Disease | denotes | liver cancer | MESH:D006528 |
| 726 | 461-469 | Disease | denotes | infected | MESH:D007239 |
| 727 | 631-650 | Disease | denotes | chronic hepatitis C | MESH:D019698 |
| 728 | 1401-1440 | Disease | denotes | Porphyria Cutanea Tarda and Hepatitis C | MESH:D017119 |
| 729 | 1527-1542 | Disease | denotes | Porphyria Tarda | MESH:D017119 |
| 730 | 1666-1708 | Disease | denotes | chronic hepatitis and rheumatoid arthritis | MESH:D001172 |
| 731 | 1725-1740 | Disease | denotes | hepatitis virus | MESH:D006525 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T26 | 0-9 | Phenotype | denotes | Hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |
| T27 | 90-103 | Phenotype | denotes | liver disease | http://purl.obolibrary.org/obo/HP_0001392 |
| T28 | 191-200 | Phenotype | denotes | cirrhosis | http://purl.obolibrary.org/obo/HP_0001394 |
| T29 | 224-236 | Phenotype | denotes | liver cancer | http://purl.obolibrary.org/obo/HP_0002896 |
| T30 | 275-284 | Phenotype | denotes | hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |
| T31 | 477-486 | Phenotype | denotes | hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |
| T32 | 631-648 | Phenotype | denotes | chronic hepatitis | http://purl.obolibrary.org/obo/HP_0200123 |
| T33 | 1429-1438 | Phenotype | denotes | Hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |
| T34 | 1666-1683 | Phenotype | denotes | chronic hepatitis | http://purl.obolibrary.org/obo/HP_0200123 |
| T35 | 1688-1708 | Phenotype | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/HP_0001370 |
| T36 | 1725-1734 | Phenotype | denotes | hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T162 | 0-237 | Sentence | denotes | Hepatitis virus, an RNA virus belonging to the Flaviviridae family, is closely related to liver disease, which in 70–80% of patients becomes chronic, resulting in major complications such as cirrhosis and, in the year, also liver cancer. |
| T163 | 238-334 | Sentence | denotes | The antiviral activity of HCQ on the hepatitis C virus (HCV) in monotherapy has not been tested. |
| T164 | 335-417 | Sentence | denotes | However, it seems that this drug increases the antiviral effect of standard drugs. |
| T165 | 418-660 | Sentence | denotes | In a study including 120 Egyptian patients infected by the hepatitis C virus, it was seen that the combination of HCQ with pegylated interferon and ribavirin could improve biochemical and virological responses in chronic hepatitis C subjects. |
| T166 | 661-918 | Sentence | denotes | All patients were randomized and divided into two groups; the control group treated with standard-of-care (SOC) consisted of 160 µg of subcutaneous pegylated interferon and 1000–12000 mg/day of oral ribavirin, and the group treated with 200 mg HCQ plus SOC. |
| T167 | 919-1095 | Sentence | denotes | At the end of the treatment (12 weeks), patients of HCQ + SOC group showed a high virological response compared to the control group (54/60 (90%) vs. 43/60 (71.7%); p = 0.011). |
| T168 | 1096-1314 | Sentence | denotes | Moreover, in the HCQ + SOC group, there was a normalization of ALT levels, as is also demonstrated by the earlier biochemical response (EBR) highlighted in HCQ + SOC group 58/60 (96.7%) than SOC group 42/60 (70%) [30]. |
| T169 | 1315-1441 | Sentence | denotes | These results were confirmed by several case reports regarding patient treatment with Porphyria Cutanea Tarda and Hepatitis C. |
| T170 | 1442-1634 | Sentence | denotes | It was seen that a low dose of HCQ (100 mg twice weekly) prevented the recurrence of Porphyria Tarda and reduced the viral response during HCV therapy, including ribavirin and interferon [45]. |
| T171 | 1635-1892 | Sentence | denotes | Furthermore, in a patient with chronic hepatitis and rheumatoid arthritis, a low risk for hepatitis virus reactivation was observed after treatment with steroids (< 7.5 mg/day), HCQ or sulfadiazine [46] in combination with antivirals as prophylaxis [47,48]. |